$10.30
0.767.97%
Pre-Market: Dec 27, 9:29 AM EDT
Comments
Loading...
Santen Pharmaceutical Stock Guidance | OTC:SNPHY | Benzinga
Santen Pharmaceutical issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/06/2025 | SNPHY | Santen Pharmaceutical | FY | 2024 | $0.77 | $0.77 | — | $1.98B | $1.98B | — | Get Alert |
| 02/07/2023 | SNPHY | Santen Pharmaceutical | FY | 2022 | $0.56 | $0.56 | — | $1.93B | $1.93B | — | Get Alert |
| 11/08/2022 | SNPHY | Santen Pharmaceutical | FY | 2022 | — | — | — | $2.03B | $2.03B | — | Get Alert |
| 08/04/2022 | SNPHY | Santen Pharmaceutical | FY | 2022 | — | — | — | $2.04B | $2.04B | — | Get Alert |
| 02/10/2022 | SNPHY | Santen Pharmaceutical | FY | 2021 | $0.94 | $0.94 | — | $2.48B | $2.48B | — | Get Alert |
| 08/06/2021 | SNPHY | Santen Pharmaceutical | FY | 2021 | $0.94 | $0.94 | — | $2.48B | $2.48B | — | Get Alert |
FAQ
What is the most recent guidance for Santen Pharmaceutical (SNPHY)?
There have been no specific sales or earnings guidance reported for Santen Pharmaceutical in recent months.
Browse guidance and forecast on all stocks.